Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients

Arthritis Care and Research

Volumn 69, Issue 11, 2017, Pages 1771-1776

  Albayda, Jemima ^a   Pinal Fernandez, Iago ^b   Huang, Wilson ^b   Parks, Cassie ^b   Paik, Julie ^a   Casciola Rosen, Livia ^a   Danoff, Sonye K ^a   Johnson, Cheilonda ^a   Christopher Stine, Lisa ^a   Mammen, Andrew L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR MATRIX PROTEIN 2 AUTOANTIBODY; AUTOANTIBODY; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; MATRIX PROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ANTINUCLEAR ANTIBODY; DNA BINDING PROTEIN; MORC3 PROTEIN, HUMAN;

ADULT; ARM WEAKNESS; ARTICLE; CALCINOSIS; CANCER RISK; CLINICAL FEATURE; COMPARATIVE STUDY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DYSPHAGIA; EDEMA; FEMALE; HUMAN; LIMB WEAKNESS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MUSCLE DISEASE; MUSCLE STRENGTH; MYALGIA; PHENOTYPE; PROSPECTIVE STUDY; BLOOD; COHORT ANALYSIS; MIDDLE AGED; MUSCLE WEAKNESS; RISK FACTOR;

ADENOSINE TRIPHOSPHATASES; ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; CALCINOSIS; COHORT STUDIES; DERMATOMYOSITIS; DNA-BINDING PROTEINS; EDEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE WEAKNESS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 85032259024     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23188     Document Type: Article

References (16)

1. Oddis CV, Fertig N, Goel A, Espada G, Confalone Gregorian M, Maldonado Cocco MA. Clinical and serological characterisation of the anti-MJ antibody in childhood myositis [abstract]. Arthritis Rheum 1997;40 Suppl:S139.
2. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012;71:710–3.
3. Betteridge Z, Gunawardena H, Chinoy H, Vencovsky J, Allard S, Gordon P. Autoantibodies to the P140 autoantigen NXP-2 in adult dermatomyositis [abstract]. Arthritis Rheum 2009;60 Suppl:815.
4. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012;14:R97.
5. Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60:1807–14.
6. Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 2014;53:2204–8.
7. Valenzuela A, Chung L, Casciola-Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 2014;150:724–9.
8. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013;65:2954–62.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344–7.
10. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis): presentation of six new cases and review of the literature. J Am Acad Dermatol 1991;24:959–66.
11. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. The 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. 2003 October 10–12; Naarden, The Netherlands. Neuromusc Disord 2004;14:337–45.
12. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti–3-hydroxy-3-methylglutaryl-coenzyme A reductase–associated autoimmune myopathy. Arthritis Rheum 2012;64:4087–93.
13. Travis WD, Costabel U, Hansell DM, King TE Jr., Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. A J Respir Crit Care Med 2013;188:733–48.
14. Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017;76:681–7.
15. Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford) 2017;56:787–94.
16. Pinal-Fernandez I, Casciola-Rosen L, Christopher-Stine L, Corse A, Mammen A. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from dermatomyositis patients. J Rheumatol 2015;42:1448–54.